Form 4: United Therapeutics CFO Exercises Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 14, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, exercised stock options and sold shares of common stock.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised options to acquire a total of 8,334 shares at exercise prices of $120.26 and $117.76.
• Simultaneously, he sold a total of 7,792 shares at a price of $355.88 per share.
• Some of the option exercises were 'sell-to-cover' transactions, where a portion of the acquired shares were immediately sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 6,426 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports routine stock transactions under a pre-arranged plan, which is a common practice. There is no indication of positive or negative implications for the company's performance.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating no insider information was used.

Industry Context

Executive stock transactions are common and closely monitored, especially in publicly traded companies like United Therapeutics. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their stock holdings in a compliant manner.
• Comparable companies such as Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares, but the effect is likely minimal given the relatively small volume of shares involved.

Key Dates